ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2025
Continuous Hemodynamic Response to Angiotensin II in Critically Ill Pediatric Patients: A Single Center Cohort Study.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of Angiotensin II as a Vasoactive Agent to Treat Distributive Shock With a Focus on Preliminary Data in Pediatric-Aged Patients.Paediatric anaesthesia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo report efficacy, safety, and dosing of angiotensin II (AT-II) in pediatric patients with refractory vasodilatory shock.
methodsThis was a single center retrospective cohort study using automated, high-fidelity hemodynamic data in a large tertiary pediatric academic medical center. Pediatric patients who required multimodal vasopressor therapy for fluid refractory vasodilatory shock and received AT-II between June 2017 and November 2022 were included. High-fidelity hemodynamic data were captured via the Etiometry T3 platform. Vasoactive-inotropic score (VIS), AT-II dosing, demographics, clinical characteristics, and potential adverse effects were collected from the electronic medical record.
resultsFourteen pediatric patients with a median age of 11.6 years (range, 13 days-16.8 years) received AT-II at a dose of 2.5 to 80 ng/kg/min for a median of 32 hours (range, 3.1-72.4). Ten of 14 patients (71%) responded favorably to AT-II therapy, experiencing a clinically significant decrease in VIS or increase in mean arterial blood pressure. The median age of responders was significantly higher than that of nonresponders (12.5 years vs 0.4 years; p = 0.002), and responders had a higher baseline VIS (56 vs 33; p = 0.008) than nonresponders. One patient (7%) experienced peripheral ischemia.
conclusionsAngiotensin II has a potential role in the management of pediatric patients with vasodilatory shock resistant to multimodal vasopressor therapy. Demographic and clinical characteristics predicting response in the pediatric population require careful, prospective evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.